Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01381133 · ClinicalTrials.gov registry record · Phase 3
Adolescent Outpatient and Continuing Care Study
A Phase 3 study, sponsored by Chestnut Health Systems.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
NCT01381133 is a Phase 3 study that has completed, run by Chestnut Health Systems. The registered enrollment target is 320 participants.
The verdict
NCT01381133, a Phase 3 study, has completed, sponsored by Chestnut Health Systems.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the effectiveness and cost-effectiveness of two types of outpatient treatment with and without Assertive Continuing Care (ACC) for 320 adolescents with substance use disorders. Study participants were randomly assigned to one of four conditions: (a) Chestnut's Bloomington Outpatient Treatment (CBOP) without ACC; (b) CBOP with ACC; (c) Motivational Enhancement Therapy/Cognitive Behavior Therapy-7 session model (MET/CBT7) without ACC; and (d) MET/CBT7 with ACC. Based on prior quasi and experimental studies, the investigators hypothesized that MET/CBT would be more effective and cost-effective than CBOP in terms of increasing days abstinent and decreasing substance abuse problems. Additionally, the investigators hypothesized that the groups receiving ACC would have significantly better outcomes than the groups without ACC. Lastly, the investigators hypothesized that adding ACC to MET/CBT would be the most cost-effective option in terms of days abstinent.
Interventions
- BEHAVIORAL Chestnut Bloomington Outpatient (CBOP)
- BEHAVIORAL Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)
- BEHAVIORAL Assertive Continuing Care (ACC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2002-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01381133
The ClinicalTrials.gov registry entry for NCT01381133 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chestnut Health Systems, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Chestnut Bloomington Outpatient (CBOP) is the first listed.
NCT01381133 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01381133 about?
NCT01381133 is a clinical study titled "Adolescent Outpatient and Continuing Care Study". The purpose of this study was to evaluate the effectiveness and cost-effectiveness of two types of outpatient treatment with and without Assertive Continuing Care (ACC) for 320 adolescents with substance use disorders. Study participants were randomly assigned to one of four conditions: (a) Chestnut...
What is the current status of trial NCT01381133?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2002-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT01381133?
The interventions under investigation include: Chestnut Bloomington Outpatient (CBOP) (BEHAVIORAL), Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7) (BEHAVIORAL), Assertive Continuing Care (ACC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT01381133?
This trial is sponsored by Chestnut Health Systems, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.